- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07319247
Thérapie au laser et entraînement des muscles du plancher pelvien pour l'incontinence urinaire d'effort
L'Effet de la Thérapie Laser à Haute Fréquence et de l'Entraînement des Muscles du Plancher Pelvien chez les Femmes Souffrant d'Incontinence Urinaire d'Effort : Un Essai Contrôlé Randomisé Placebo
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Konya
-
Meram, Konya, Turquie (Türkiye), (507) 534-6142
- Physical Therapy Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Critères d'inclusion :
- Femmes âgées de 18 à 65 ans,
- Femmes volontaires et engagées dans leur travail,
- Femmes diagnostiquées avec une incontinence urinaire d'effort,
Critères d'exclusion :
- Grossesse,
- Chirurgie antérieure dans la zone de traitement dans les 12 derniers mois,
- Infection génitale active,
- Présence de malignité,
- Utilisation de stéroïdes systémiques au cours des 3 derniers mois,
- Utilisation de lubrifiant vaginal dans les 7 derniers jours,
- Infections urinaires récurrentes ou herpès génital,
- Score POP-Q de 3 ou plus
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur placebo: Plasebo Laser
This group will only receive placebo laser treatment.
The ND: YAG laser system was configured identically, except for the addition of a metal shielding plate to the hand tool to block energy, which had no therapeutic effect, during treatment.
The laser device will be aimed at 6 points in the perineal area .
Assessments will be conducted twice, baseline and post treatment (at 12 weeks).
|
This group will only receive placebo laser treatment.
The ND: YAG laser system was configured identically, except for the addition of a metal shielding plate to the hand tool to block energy, which had no therapeutic effect, during treatment.
The laser device will be aimed at 6 points in the perineal area .
Assessments will be conducted twice, baseline and post treatment (at 12 weeks).
|
|
Comparateur actif: PFME
In this training, patients are taught pelvic floor exercises, which involve slow and fast muscle contractions that train both Type 1 and Type 2 muscle fibers, using vaginal palpation.
During fast contractions, patients are asked to quickly contract and relax their pelvic floor muscles.
The image of "turning the faucet off and on" is used to help patients better understand this exercise.
During slow contractions, patients are asked to slowly tighten their pelvic floor muscles, hold them for 10 seconds, and then slowly relax them.
One set of pelvic floor muscle exercises consists of 10 fast contractions and 10 slow contractions.
According to this program, pelvic floor exercises are performed in weeks 1-2, 2 sets in weeks 3-4, 4 sets in weeks 5-6, 8 sets in weeks 7-8, and 10 sets in weeks 8-12.
Assessments will be conducted twice, baseline and post treatment (at 12 week).
|
In this training, patients are taught pelvic floor exercises, which involve slow and fast muscle contractions that train both Type 1 and Type 2 muscle fibers, using vaginal palpation.
During fast contractions, patients are asked to quickly contract and relax their pelvic floor muscles.
The image of "turning the faucet off and on" is used to help patients better understand this exercise.
During slow contractions, patients are asked to slowly tighten their pelvic floor muscles, hold them for 10 seconds, and then slowly relax them.
One set of pelvic floor muscle exercises consists of 10 fast contractions and 10 slow contractions.
According to this program, pelvic floor exercises are performed in weeks 1-2, 2 sets in weeks 3-4, 4 sets in weeks 5-6, 8 sets in weeks 7-8, and 10 sets in weeks 8-12.
Assessments will be conducted twice, baseline and post treatment (at 12 week).
|
|
Expérimental: PFME and Laser Therapy
PFMT, patients are taught pelvic floor exercises, which involve slow and fast muscle contractions that train both Type 1 and Type 2 muscle fibers, using vaginal palpation.
During fast contractions, patients are asked to quickly contract and relax their pelvic floor muscles.
The image of "turning the faucet off and on" is used to help patients better understand this exercise.
During slow contractions, patients are asked to slowly tighten their pelvic floor muscles, hold them for 10 seconds, and then slowly relax them.
One set of pelvic floor muscle exercises consists of 10 fast contractions and 10 slow contractions.
Assessments will be conducted twice, baseline and post treatment (at 12 weeks).
Laser was also applied to this group.
Laser application is applied to 6 points in the perineal area.
Continue and biostimulatory mode, intensity 6W, energy density 120J/cm2.
Application time is 2 minutes for each point, and a total of 6 sessions are applied 3 time.
|
PFMT, patients are taught pelvic floor exercises, which involve slow and fast muscle contractions that train both Type 1 and Type 2 muscle fibers, using vaginal palpation. During fast contractions, patients are asked to quickly contract and relax their pelvic floor muscles. The image of "turning the faucet off and on" is used to help patients better understand this exercise. During slow contractions, patients are asked to slowly tighten their pelvic floor muscles, hold them for 10 seconds, and then slowly relax them. One set of pelvic floor muscle exercises consists of 10 fast contractions and 10 slow contractions. According to this program, pelvic floor exercises are performed in weeks 1-2, in weeks 3-4, in weeks 5-6, in weeks 8-12, and in weeks 12. Laser application is applied to 6 points in the perineal area. Continue and biostimulatory mode, intensity 6W, energy density 120J/cm2. Application time is 2 minutes for each point, and a total of 6 sessions are applied 3 time |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Urinary incontinence severity
Délai: baseline, post treatment (at 12 week)
|
The Incontinence Severity Index (ISI): This is a two-question questionnaire that helps calculate the severity of urinary incontinence in patients.
It categorizes incontinence severity into three groups: mild, moderate, and severe.
It is a useful method for monitoring and assessing incontinence severity.
|
baseline, post treatment (at 12 week)
|
|
The impact of urinary incontinence on quality of life
Délai: baseline, post treatment (at 12 week)
|
The Incontinence Quality of Life Scale (I-QOL) will be used to determine the impact of urinary incontinence on quality of life in women.
It consists of questions under three headings: behavioral, psychological, and social impact.
The questions will be asked of the participants and recorded.
|
baseline, post treatment (at 12 week)
|
|
pelvic floor dysfuntion severity
Délai: baseline, post treatment (at 12 week)
|
The Global Pelvic Floor Impact Questionnaire (GPTRA): This questionnaire consists of nine questions addressing pelvic floor dysfunction.
A higher total score indicates a greater degree of symptoms.
Participants were asked questions and recorded.
|
baseline, post treatment (at 12 week)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Sexually Dysfunction
Délai: baseline, post treatment (at 12 week)
|
The Female Sexual Function Index (FSFI): It consists of nineteen separate questions. It has six subscales: desire, arousal, lubrication, orgasm, general satisfaction, and pain. Questions 3-14 and 15-19 are scored on a 6-point Likert-type scale (0-5), while the remaining questions are scored on a 5-point Likert-type scale (1-5). The scale, which can be applied to those who have had sexual intercourse within the last month, is scored negatively, with higher scores interpreted as indicating no or low sexual dysfunction. The highest possible score is 36.0, and the lowest is 2.0. The cut-off score is 26.55. Scores of 26.55 and below are considered to indicate sexual dysfunction. |
baseline, post treatment (at 12 week)
|
|
pelvic floor muscle function
Délai: baseline, post treatment (at 12 week)
|
Pelvic floor muscle function will be assessed with EMG biofeedback.
|
baseline, post treatment (at 12 week)
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Maladies urogénitales masculines
- Maladies urologiques
- Maladies urogénitales féminines
- Maladies urogénitales féminines et complications de la grossesse
- Troubles urinaires
- Symptômes des voies urinaires inférieures
- Manifestations urologiques
- Conditions pathologiques, signes et symptômes
- Signes et symptômes
- Incontinence urinaire
- Incontinence urinaire, Stress
- Thérapeutique
- Procédures chirurgicales, opératoires
- Techniques d'ablation
- Thérapie au laser
- ester méthylique de la pentalénolactone F
Autres numéros d'identification d'étude
- hlaser
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .